MedTrace Logo

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

NCT07611110 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 670

Last updated 2026-05-28

No results posted yet for this study

Summary

The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.

Conditions

Interventions

DRUG

AZD2265

IV

DRUG

Cabazitaxel

IV in combination with oral prednisone/prednisolone

DRUG

Abiraterone

Oral in combination with prednisone/prednisolone

DRUG

Enzalutamide

Oral

DRUG

Apalutamide

Oral

DRUG

Darolutamide

Oral

DRUG

Rezvilutamide

Oral

DRUG

Radium-223

IV

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-04
Primary Completion
2029-02-13
Completion
2029-12-20
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Austria
  • Brazil
  • Canada
  • China
  • France
  • Germany
  • India
  • Japan
  • South Korea
  • Spain
  • Taiwan
  • Thailand
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07611110 on ClinicalTrials.gov